Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMBRIEL: Tozorakimab Dose Range Finding in Uncontrolled Asthma
2024-519116-14-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Tozorakimab dose-ranging arm with Placebo arm (2 arms). Primary endpoint: Annualised rate of severe asthma exacerbations. Planned start May 2025; status: authorised.
02
Drugs
tozorakimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-519116-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519116-14-00.